close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ferring Pharmaceuticals

< Previous 1 2 Next >
Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement
From Ferring Pharmaceuticals
Via Business Wire
New Data Show Durable Response Following Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg)
From Ferring Pharmaceuticals
Via Business Wire
ACG 2023 Presentations for REBYOTA® (fecal microbiota, live – jslm) Explore Association Between Gut Microbiome Composition and Health-Related Quality of Life and Evaluate Efficacy and Safety in Older Patients With Comorbidities
From Ferring Pharmaceuticals
Via Business Wire
More Real-World Data and New Analyses of Data for REBYOTA® (fecal microbiota, live – jslm) Presented at IDWeek 2023
From Ferring Pharmaceuticals
Via Business Wire
Ferring to Present New Data Analyses at ACG 2023 for REBYOTA® (fecal microbiota, live – jslm), the First and Only Single-Dose, FDA Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection
From Ferring Pharmaceuticals
Via Business Wire
Ferring to Present New Data Analyses at IDWeek 2023 for REBYOTA® (fecal microbiota, live – jslm), the First and Only Single-Dose, FDA Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection
From Ferring Pharmaceuticals
Via Business Wire
First Bladder Cancer Patient Dosed with Commercially Available Intravesical Gene Therapy ADSTILADRIN® (nadofaragene firadenovec-vncg)
From Ferring Pharmaceuticals
Via Business Wire
Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)
From Ferring Pharmaceuticals
Via Business Wire
Tickers RPRX
Largest Integrated Safety Analysis From Five Prospective Clinical Trials for REBYOTA® (fecal microbiota, live – jslm) Published in Therapeutic Advances in Gastroenterology
From Ferring Pharmaceuticals
Via Business Wire
Ferring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors
From Ferring Pharmaceuticals
Via Business Wire
Ferring Pharmaceuticals successfully increases its second Swiss Franc Bond offering by CHF 80 million
From Ferring Pharmaceuticals
Via Business Wire
Ferring Pharmaceuticals Receives U.S. FDA Approval of Drug Substance Manufacturing Scale-up Process for Gene Therapy ADSTILADRIN® (nadofaragene firadenovec-vncg)
From Ferring Pharmaceuticals
Via Business Wire
Ferring Announces Positive Topline Phase 3 Results for SI-6603, an Investigational Treatment for Lumbar Disc Herniation
From Ferring Pharmaceuticals
Via Business Wire
Four Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, Presented at DDW 2023
From Ferring Pharmaceuticals
Via Business Wire
Retrospective Analysis of Data Evaluating Safety and Efficacy of REBYOTA™ (fecal microbiota, live – jslm) in a Real-World Patient Population with Comorbidities and Risk Factors Published in Open Forum Infectious Diseases
From Ferring Pharmaceuticals
Via Business Wire
Ferring to Present Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, at DDW 2023
From Ferring Pharmaceuticals
Via Business Wire
Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health
From Ferring Pharmaceuticals
Via Business Wire
Ferring Announces Abstract of the First Prospective, Multi-National, Real-world Study of Rekovelle® (follitropin delta) at the Congress of the Pacific Society for Reproductive Medicine
From Ferring Pharmaceuticals
Via Business Wire
Ferring Pharmaceuticals Announces Availability of REBYOTA™ (fecal microbiota, live – jslm) – the First and Only FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrence of C. diff Infection in Adults
From Ferring Pharmaceuticals
Via Business Wire
Ferring Receives U.S. FDA Approval for REBYOTA® (fecal microbiota, live-jslm) – A Novel First-in-Class Microbiota-Based Live Biotherapeutic
From Ferring Pharmaceuticals
Via Business Wire
Pivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in Drugs
From Ferring Pharmaceuticals
Via Business Wire
Ferring Presents Seven New Analyses at ACG 2022 for RBX2660, Its Investigational Microbiota-Based Live Biotherapeutic
From Ferring Pharmaceuticals
Via Business Wire
Ferring Presents New Subgroup Analyses of Health-Related Quality of Life and Safety and Efficacy Data at IDWeek 2022 for RBX2660, Its Investigational Microbiota-based Live Biotherapeutic
From Ferring Pharmaceuticals
Via Business Wire
Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at ACG 2022
From Ferring Pharmaceuticals
Via Business Wire
Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at IDWeek 2022
From Ferring Pharmaceuticals
Via Business Wire
Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660
From Ferring Pharmaceuticals
Via Business Wire
Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic
From Ferring Pharmaceuticals
Via Business Wire
Ferring Announces New Collaboration for Development of Olamkicept
From Ferring Pharmaceuticals
Via Business Wire
Ferring Presents New Analyses of Efficacy, Safety and Microbiome Composition Data at DDW 2022 for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic
From Ferring Pharmaceuticals
Via Business Wire
Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at DDW 2022
From Ferring Pharmaceuticals
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today